Nuvalent, Inc.
NASDAQ: NUVL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- James R. Porter
- Employees
- 162
- Headquarters
- Cambridge, United States
- IPO year
- 2021
- Market cap
- $9.1B
- Website
- https://www.nuvalent.com
Loading NUVL…
Loading profile data…Frequently asked questions about NUVL
What does Nuvalent, Inc. (NUVL) do?
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target...
Where does NUVL trade?
Nuvalent, Inc. (NUVL) trades on the NASDAQ Global Select.
What sector is NUVL in?
Nuvalent, Inc. (NUVL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Nuvalent, Inc.?
James R. Porter is the chief executive officer of Nuvalent, Inc. (NUVL).
Where is Nuvalent, Inc. headquartered?
Nuvalent, Inc. is headquartered in United States.
Does NUVL pay a dividend?
Nuvalent, Inc. (NUVL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NUVL go public?
Nuvalent, Inc. (NUVL) completed its initial public offering in 2021.